| 1 |
33674562 | Ciclopirox and bortezomib synergistically inhibits glioblastoma multiforme growth via simultaneously enhancing JNK/p38 MAPK and NF-κB signaling. | 2021 Mar 5 |
3 |
| 2 |
33787860 | Antineoplastic and anti-inflammatory effects of bortezomib on systemic chronic active EBV infection. | 2021 Apr 13 |
1 |
| 3 |
34144391 | Proteasome dysfunction under compromised redox metabolism dictates liver injury in NASH through ASK1/PPARγ binodal complementary modules. | 2021 Sep |
1 |
| 4 |
29259009 | Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression. | 2018 Mar 1 |
1 |
| 5 |
29423023 | Infliction of proteotoxic stresses by impairment of the unfolded protein response or proteasomal inhibition as a therapeutic strategy for mast cell leukemia. | 2018 Jan 9 |
2 |
| 6 |
30094097 | Trametinib suppresses chemotherapy-induced cold and mechanical allodynia via inhibition of extracellular-regulated protein kinase 1/2 activation. | 2018 |
3 |
| 7 |
29026157 | Bortezomib promotes KHSV and EBV lytic cycle by activating JNK and autophagy. | 2017 Oct 12 |
2 |
| 8 |
27390350 | Bortezomib Treatment Sensitizes Oncolytic HSV-1-Treated Tumors to NK Cell Immunotherapy. | 2016 Nov 1 |
1 |
| 9 |
25602436 | Bortezomib inhibits gastric carcinoma HGC-27 cells through the phospho-Jun N-terminal kinase (p-JNK) pathway in vitro. | 2015 Apr 1 |
2 |
| 10 |
24190701 | Bortezomib-induced apoptosis in cultured pancreatic cancer cells is associated with ceramide production. | 2014 Jan |
3 |
| 11 |
24486574 | Role of Bcl-xL/Beclin-1 in interplay between apoptosis and autophagy in oxaliplatin and bortezomib-induced cell death. | 2014 Mar 15 |
1 |
| 12 |
22006557 | Involvement of mitogen-activated protein kinase in signal transducer and activator of transcription-1 mediated differentiation induced by bortezomib in acute myeloid leukemia cells. | 2013 Jan |
3 |
| 13 |
23079083 | Bortezomib/proteasome inhibitor triggers both apoptosis and autophagy-dependent pathways in melanoma cells. | 2013 Jan |
2 |
| 14 |
24086672 | JNK and macroautophagy activation by bortezomib has a pro-survival effect in primary effusion lymphoma cells. | 2013 |
4 |
| 15 |
24158003 | Combination treatment with 2-methoxyestradiol overcomes bortezomib resistance of multiple myeloma cells. | 2013 Oct 25 |
3 |
| 16 |
21732139 | Inhibition of heat shock protein response enhances PS-341-mediated glioma cell death. | 2012 Jul |
1 |
| 17 |
21993018 | Bortezomib induces autophagy in head and neck squamous cell carcinoma cells via JNK activation. | 2012 Jan 1 |
6 |
| 18 |
22532603 | Proteasome inhibition blocks NF-κB and ERK1/2 pathways, restores antigen expression, and sensitizes resistant human melanoma to TCR-engineered CTLs. | 2012 Jun |
1 |
| 19 |
22606012 | Curcumin enhances cytotoxic effects of bortezomib in human multiple myeloma H929 cells: potential roles of NF-κB/JNK. | 2012 |
1 |
| 20 |
22822672 | [Effects of secoisolariciresinol diglucoside combined with bortezomib on induction of apoptosis in lung cancer cell line A549]. | 2012 Feb |
1 |
| 21 |
23257432 | [Mechanism of apoptosis synergistically induced by bortezomib combined with cytarabine in U937 cell line]. | 2012 Dec |
1 |
| 22 |
21729547 | [Effect of different concentrations of bortezomib on the expression of ERK, JNK and P38 in daunorubicin-resistant K562 cells]. | 2011 Jun |
5 |
| 23 |
21755010 | Small compound 6-O-angeloylplenolin induces mitotic arrest and exhibits therapeutic potentials in multiple myeloma. | 2011 |
1 |
| 24 |
22087283 | The proteasome inhibitor bortezomib enhances ATRA-induced differentiation of neuroblastoma cells via the JNK mitogen-activated protein kinase pathway. | 2011 |
2 |
| 25 |
19267218 | Bmf is upregulated by PS-341-mediated cell death of glioma cells through JNK phosphorylation. | 2010 Mar |
1 |
| 26 |
19608275 | Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition. | 2010 Jan |
1 |
| 27 |
21176351 | [Effect of bortezomib on MAPK signaling pathway of K562/DNR cells]. | 2010 Dec |
2 |
| 28 |
19270531 | Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress. | 2009 May |
4 |
| 29 |
18559525 | The novel polyamine analogue CGC-11093 enhances the antimyeloma activity of bortezomib. | 2008 Jun 15 |
2 |
| 30 |
16528474 | JNK and AP-1 mediate apoptosis induced by bortezomib in HepG2 cells via FasL/caspase-8 and mitochondria-dependent pathways. | 2006 Apr |
3 |
| 31 |
16985072 | Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. | 2006 Sep |
1 |
| 32 |
15531918 | Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). | 2005 Jan 13 |
1 |
| 33 |
15735676 | Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors. | 2005 Apr 28 |
6 |
| 34 |
16357177 | Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. | 2005 Dec 15 |
3 |
| 35 |
14965369 | Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling. | 2004 Feb |
9 |
| 36 |
15093752 | The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib. | 2004 May 1 |
6 |
| 37 |
15217830 | Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. | 2004 Oct 15 |
5 |
| 38 |
12393500 | Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. | 2003 Feb 15 |
3 |